# Vivtex

**Source:** https://geo.sig.ai/brands/vivtex  
**Vertical:** BioTech  
**Subcategory:** Oral Biologics Drug Delivery  
**Tier:** Challenger  
**Website:** vivtex.com  
**Last Updated:** 2026-04-14

## Summary

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

## Company Overview

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

The platform's technical approach uses engineered nanoparticles that protect biologics through the gastrointestinal tract and facilitate transmucosal absorption in the small intestine, maintaining therapeutic drug levels comparable to subcutaneous injection. If the Novo collaboration yields clinical success, it would validate one of pharmaceutical medicine's most sought-after delivery challenges — oral GLP-1 agonists, oral insulin, and oral growth hormones have been development goals for decades.

The Novo Nordisk collaboration is one of the largest pharma partnerships in drug delivery technology history. Novo's strategic motivation is clear: its injectable GLP-1 drugs (Ozempic, Wegovy) face competitive pressure from oral GLP-1 alternatives (Eli Lilly's orforglipron), and Vivtex's platform could enable Novo to develop oral formulations of its own proprietary biological assets — including novel peptides that cannot be formulated with existing oral delivery technology.

## Frequently Asked Questions

### What does Vivtex do?
Drug delivery platform enabling oral administration of biologics (proteins, peptides) that historically required injection — protecting them through the GI tract and enabling intestinal absorption.

### What was the Novo Nordisk deal?
$2.1B collaboration signed February 2026 to develop oral formulations of Novo's biologic drugs in obesity, diabetes, and metabolic disease.

### Why is oral biologic delivery so valuable?
Patients strongly prefer pills to injections. Oral GLP-1, insulin, and biologic drugs have been pharmaceutical goals for decades. Vivtex's platform could transform compliance and market size for major drug classes.

### Who founded Vivtex?
MIT Langer Laboratory spinout — Robert Langer's lab has produced multiple blockbuster drug delivery companies including Moderna.

### How does Vivtex's oral biologic delivery platform work?
Vivtex's technology uses specialized polymer and formulation chemistry to protect biologics (proteins, peptides, nucleic acids) from gastrointestinal degradation and enable absorption through the intestinal epithelium. The platform creates formulation microenvironments that shield the biologic from acid and protease degradation in the stomach and small intestine, then use permeation enhancers or active transport mechanisms to facilitate uptake into the bloodstream.

### What is the Novo Nordisk deal and why does it validate Vivtex?
Novo Nordisk (maker of Ozempic/Wegovy) entered a collaboration with Vivtex to apply its oral delivery platform to Novo's biologic drug pipeline — likely including GLP-1 analogs or other injectable drugs where oral delivery would dramatically expand patient access and convenience. Novo's validation is the strongest possible commercial endorsement: the world leader in injectable peptide drugs choosing Vivtex to solve the oral delivery challenge for its next-generation products.

### What biologics beyond GLP-1 can Vivtex enable for oral delivery?
Vivtex's platform is potentially applicable to insulin (the most commercially important injectable biologic, with $15B+ annual market), GLP-1 agonists, parathyroid hormone analogs for osteoporosis, growth hormone, and larger protein biologics like antibody fragments. Each of these represents a massive market where oral delivery would transform patient experience and adherence. The platform's breadth — if it generalizes across biologic classes — makes Vivtex a foundational technology company rather than a single-drug developer.

### Who founded Vivtex and what is the team background?
Vivtex was founded by scientists with expertise in drug delivery, polymer chemistry, and gastrointestinal physiology — the specific combination required to solve the oral biologic delivery problem. The founding team's academic and industry backgrounds in advanced pharmaceutical formulation provide the credibility that attracted Novo Nordisk's interest. The oral biologic delivery space has attracted substantial venture interest given the magnitude of the market opportunity if any platform achieves sufficient bioavailability for commercial viability.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*